Quality of Life Assessed by the Questionnaire MOS SF-36 in Bladder Cancer Patients Depending on the Method of Surgical Treatment
DOI:
https://doi.org/10.15407/exp-oncology.2024.04.351Keywords:
quality of life, questionnaire, bladder cancer, radical cystectomy, organ-sparring treatmentAbstract
Using the Ukrainian version of the Medical Outcomes Study Short Form, MOS SF-36 questionnaire for assessment of quality of life (QoL), a prospective analysis of the QoL of patients with bladder cancer who underwent radical surgery in the scope of radical cystectomy (group 1, 15 patients) and organ-preserving surgeries (bladder resection or transurethral resection, group 2, 40 patients) was conducted in the period from 2020 to 2022 at the Center for Urology and Urologic Oncology of the Feofania Clinical Hospital. The survey was conducted 1 week before radical surgery and 6 months after surgery. None of the studied patients had signs of recurrence or progression of bladder cancer during the postoperative survey. With identical QoL indicators before surgery, patients who underwent organ-preserving surgeries demonstrated significantly higher QoL indicators, such as physical, role, social, emotional functioning, and psychological health.
References
The World Health Organization Quality of Life. WHOQOL User Manual.: World Health Organization.; 2012. p. 106. https://www.who.int/publications/i/item/WHO-HIS-HSI-Rev.2012-3
Li ZJ, Wang DY, Liu ZH. Clinical efficacy and quality of life assessment of partial cystectomy and plasmakinetic trans- urethral resection of tumor in bladder cancer patients. Cancer Manag Res. 2022;14:389-398. https://doi.org/10.2147/ CMAR.S346764
Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in mus- cle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120-137. https://doi.org/10.1016/j.euru- ro.2014.02.038
Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for in- vasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys. 2011;79(1):172-178. https://doi.org/10.1016/j.ijrobp.2009.10.038
Feuerstein MA, Goenka A. Quality of life outcomes for bladder cancer patients undergoing bladder preservation with radiotherapy. Curr Urol Rep. 2015;16(11):75. https://doi.org/10.1007/s11934-015-0547-1
van der Veen JH, van Andel G, Kurth KH. Quality-of-life assessment in bladder cancer. World J Urol. 1999;17(4):219- 224. https://doi.org/10.1007/s003450050136
Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol. 2007;4(3):147-
https://doi.org/10.1038/ncpuro0750
Feshchenko YuI, Mostovoy YuM, Babiychuk Yu. Procedure for adapting the international questionnaire for assessing the quality of life MOS SF-36 in Ukraine. Experience of its use in patients with bronchial asthma. Ukr Pulmonol J. 2002;3:9-11.
Gilbert SM, Dunn RL, Hollenbeck BK, et al. Development and validation of the Bladder Cancer Index: a compre- hensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol. 2010;183(5):1764-1769. https://doi.org/10.1016/j.juro.2010.01.013
Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Onco- logy. J Natl Compr Canc Netw. 2020;18(3):329-354. https://doi.org/10.6004/jnccn.2020.0011
Siracusano S, Zaka A, Bassi P, et al. Quality-of-life outcomes in female patients with ileal conduit or orthotopic neo- bladder urinary diversion: 6-month results of a multicenter prospective study. Front Oncol. 2022;12:855546. https:// doi.org/10.3389/fonc.2022.855546
Yang M, Wang H, Wang J, Ruan M. Impact of invasive bladder cancer and orthotopic urinary diversion on ge- neral health-related quality of life: An SF-36 survey. Mol Clin Oncol. 2013;1(4):758-762. https://doi.org/10.3892/ mco.2013.125
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
